HER1: Reducing the Impact of Ovarian sTimulation – RIOT A
Hormonal stimulation in connection with follicular growth and maturation is presently not optimal to secure the best embryo implantation following transfer. It has become evident that a number of challenges remains to be overcome to improve IVF outcome. Artificial gonadotropin ovarian stimulation can have a detrimental effect on receptivity of the uterus surface and may lead to a potential serious condition called Ovarian HyperStimulation Syndrome (OHSS).
This projects seeks to determine whether estradiol suppression achieved by treatment with a compound called Letrozole – that inhibits estradiol formation – improves the conditions for the transfer of the embryo to the uterus and subsequently pregnancy outcome.
128 women with normal ovarian function are randomised to either additional treatment to the standardised IVF hormonal treatment with Letrozole or placebo.
The effect of the treatment will be monitored through different primary and secondary outcome parameters where serum concentration of progesterone on day of hCG (human Chorion Gonatropin) and amount of estradiol and progesterone secreted are the most important. It is expected that Letrozole significantly will reduced the hormonal secretion compared to placebo. The ultimate outcome – number of normal pregnancies – will also be compared between the groups.
This study is a collaboration between the key investigator at Herlev Hospital and the fertility clinics at Rigshospitalet, Hvidovre, Holbæk and Malmø.
This new intervention in the current IVF treatment can have very important implications for the future fertility treatment by ensuring a much safer method with a higher success rate without the feared side effects of ovarian hyperstimulation.